Homocystinuria: Therapeutic approach

Clinica Chimica Acta

Volumn 458, Issue , 2016, Pages 55-62

  Kumar, Tarun ^a   Sharma, Gurumayum Suraj ^a   Singh, Laishram Rajendrakumar ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Cystathionine synthase; Dietary treatment of homocystinuria; Homocysteine toxicity; Homocystinuria; New therapeutic strategies; Protein homocysteinylation

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; BETAINE; BLEOMYCIN HYDROLASE; CHAPERONE; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; HOMOCYSTEINE THIOLACTONE; METHIONINE; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; REACTIVE OXYGEN METABOLITE; SULFUR; MOLECULAR LIBRARY;

DETOXIFICATION; DIET RESTRICTION; ENZYME ACTIVITY; GENE MUTATION; HOMOCYSTINURIA; HUMAN; NEUROLOGICAL COMPLICATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN MODIFICATION; REVIEW; VITAMIN INTAKE; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULAR LIBRARY; PH; PHARMACOLOGY;

BETAINE; CYSTATHIONINE BETA-SYNTHASE; HOMOCYSTINURIA; HUMANS; HYDROGEN-ION CONCENTRATION; OXIDATIVE STRESS; SMALL MOLECULE LIBRARIES; VITAMIN B 12; VITAMIN B 6;

EID: 84965044043     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.04.002     Document Type: Review

References (107)

1. Chen P., Poddar R., Tipa E.V., et al. Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv. Enzym. Regul. 1999, 39:93-109.
2. Perla-Kajan J., Twardowski T., Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids 2007, 32:561-572.
3. Selhub J. Homocysteine metabolism. Annu. Rev. Nutr. 1999, 19:217-246.
4. R D.S. Inherited disorders of folate transport and metabolism. The Metabolic and Molecular Bases of Inherited Disease 1995, 3111-3128. McGraw-Hill, New-York. C.R.B.A. Scriver, S. Sly, D. Valle (Eds.).
5. Gellekink H., den Heijer M., Heil S.G., Blom H.J. Genetic determinants of plasma total homocysteine. Semin. Vasc. Med. 2005, 5:98-109.
6. Refsum H., Ueland P.M., Nygard O., Vollset S.E. Homocysteine and cardiovascular disease. Annu. Rev. Med. 1998, 49:31-62.
7. Seshadri S. Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease?. J. Alzheimers Dis. 2006, 9:393-398.
8. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 1999, 13:2277-2283.
9. White A.R., Huang X., Jobling M.F., et al. Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J. Neurochem. 2001, 76:1509-1520.
10. Jacobsen D.W. Homocysteine and vitamins in cardiovascular disease. Clin. Chem. 1998, 44:1833-1843.
11. Wilcken D.E., Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J. Clin. Invest. 1976, 57:1079-1082.
12. Mattson M.P., Shea T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003, 26:137-146.
13. Ho P.I., Ashline D., Dhitavat S., et al. Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol. Dis. 2003, 14:32-42.
14. Ho P.I., Collins S.C., Dhitavat S., et al. Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J. Neurochem. 2001, 78:249-253.
15. Steegers-Theunissen R.P., Boers G.H., Trijbels F.J., et al. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects?. Metabolism 1994, 43:1475-1480.
16. Eskes T.K., Steegers-Theunissen R.P. Primary prevention of neural-tube defects with folic acid. Eur. J. Obstet. Gynecol. Reprod. Biol. 1994, 53:147-152.
17. Rahman M. Homocystinuria. Review of four cases. Br. J. Ophthalmol. 1971, 55:338-342.
18. Wu L.L., Wu J.T. Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clin. Chim. Acta 2002, 322:21-28.
19. Lin J., Lee I.M., Song Y., et al. Plasma homocysteine and cysteine and risk of breast cancer in women. Cancer Res. 2010, 70:2397-2405.
20. Jacobsen D.W. Hyperhomocysteinemia and oxidative stress: time for a reality check?. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1182-1184.
21. Perna A.F., Ingrosso D., De Santo N.G. Homocysteine and oxidative stress. Amino Acids 2003, 25:409-417.
22. Stolzenberg-Solomon R.Z., Albanes D., Nieto F.J., et al. Pancreatic cancer risk and nutrition-related methyl-group availability indicators in male smokers. J. Natl. Cancer Inst. 1999, 91:535-541.
23. Croteau D.L., Bohr V.A. Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells. J. Biol. Chem. 1997, 272:25409-25412.
24. Shen H.M., Ong C.N. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat. Res. 1996, 366:23-44.
25. Nishio E., Watanabe Y. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide. Br. J. Pharmacol. 1997, 122:269-274.
26. Lang D., Kredan M.B., Moat S.J., et al. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. Arterioscler. Thromb. Vasc. Biol. 2000, 20:422-427.
27. Filip C., Albu E., Zamosteanu N., et al. Hyperhomocysteinemia's effect on antioxidant capacity in rats. Central European Journal of Medicine 2010, 5:620-626.
28. Jacobsen D.W., Catanescu O., Dibello P.M., Barbato J.C. Molecular targeting by homocysteine: a mechanism for vascular pathogenesis. Clin. Chem. Lab. Med. 2005, 43:1076-1083.
29. Jakubowski H. Homocysteine is a protein amino acid in humans implications for homocysteine-linked disease. J. Biol. Chem. 2002, 277:30425-30428.
30. Carter D.C., Ho J.X. Structure of serum albumin. Adv. Protein Chem. 1994, 45:153-203.
31. Hultberg B., Andersson A., Isaksson A. Protein binding of homocysteine and other thiols in HeLa cell cultures after addition of homocysteine and copper ions. Clin. Chim. Acta 1998, 269:175-184.
32. Jakubowski H. The molecular basis of homocysteine thiolactone-mediated vascular disease. Clin. Chem. Lab. Med. 2007, 45:1704-1716.
33. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J. Biol. Chem. 1997, 272:1935-1942.
34. Jakubowski H., Zhang L., Bardeguez A., Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ. Res. 2000, 87:45-51.
35. Jakubowski H., Goldman E. Synthesis of homocysteine thiolactone by methionyl-tRNA synthetase in cultured mammalian cells. FEBS Lett. 1993, 317:237-240.
36. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 2000, 275:3957-3962.
37. Anderson R.F., Packer J.E. The radiolysis of aqueous solutions of homocysteinethiolactone hydrochloride. Int. J. Radiat. Phys. Chem. 1974, 6:33-46.
38. Jakubowski H. Mechanism of the condensation of homocysteine thiolactone with aldehydes. Chem. Eur. J. 2006, 12:8039-8043.
39. Jalili S., Yousefi R., Papari M.M., Moosavi-Movahedi A.A. Effect of homocysteine thiolactone on structure and aggregation propensity of bovine pancreatic insulin. Protein J. 2011, 30:299-307.
40. Khazaei S., Yousefi R., Alavian-Mehr M.M. Aggregation and fibrillation of eye lens crystallins by homocysteinylation; implication in the eye pathological disorders. Protein J. 2012, 31:717-727.
41. Paoli P., Sbrana F., Tiribilli B., et al. Protein N-homocysteinylation induces the formation of toxic amyloid-like protofibrils. J. Mol. Biol. 2010, 400:889-907.
42. Stroylova Y.Y., Chobert J.M., Muronetz V.I., Jakubowski H., Haertle T. N-homocysteinylation of ovine prion protein induces amyloid-like transformation. Arch. Biochem. Biophys. 2012, 526:29-37.
43. Stroylova Y.Y., Zimny J., Yousefi R., et al. Aggregation and structural changes of alpha(S1)-, beta- and kappa-caseins induced by homocysteinylation. Biochim. Biophys. Acta 1814, 2011:1234-1245.
44. Obeid R., Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett. 2006, 580:2994-3005.
45. Binder C.J., Chang M.K., Shaw P.X., et al. Innate and acquired immunity in atherogenesis. Nat. Med. 2002, 8:1218-1226.
46. Sikora M., Marczak L., Kubalska J., Graban A., Jakubowski H. Identification of N-homocysteinylation sites in plasma proteins. Amino Acids 2014, 46:235-244.
47. Undas A., Perla J., Lacinski M., Trzeciak W., Kazmierski R., Jakubowski H. Autoantibodies against N-homocysteinylated proteins in humans: implications for atherosclerosis. Stroke 2004, 35:1299-1304.
48. Yap S., Naughten E. Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control. J. Inherit. Metab. Dis. 1998, 21:738-747.
49. Yap S., Rushe H., Howard P.M., Naughten E.R. The intellectual abilities of early-treated individuals with pyridoxine-nonresponsive homocystinuria due to cystathionine beta-synthase deficiency. J. Inherit. Metab. Dis. 2001, 24:437-447.
50. Linnebank M., Janosik M., Kozich V., et al. The cystathionine beta-synthase (CBS) mutation c.1224-2A>C in Central Europe: vitamin B6 nonresponsiveness and a common ancestral haplotype. Hum. Mutat. 2004, 24:352-353.
51. Kraus J.P., Janosik M., Kozich V., et al. Cystathionine beta-synthase mutations in homocystinuria. Hum. Mutat. 1999, 13:362-375.
52. Picker J.D., Levy H.L. Homocystinuria Caused by Cystathionine Beta-synthase Deficiency 2011.
53. Shoji Y., Takahashi T., Sato W., Takada G. Acute life-threatening event with rhabdomyolysis after starting on high-dose pyridoxine therapy in an infant with homocystinuria. J. Inherit. Metab. Dis. 1998, 21:439-440.
54. Schwahn B.C., Hafner D., Hohlfeld T., Balkenhol N., Laryea M.D., Wendel U. Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. Br. J. Clin. Pharmacol. 2003, 55:6-13.
55. Singh L.R., Poddar N.K., Dar T.A., Rahman S., Kumar R., Ahmad F. Forty years of research on osmolyte-induced protein folding and stability. J. Iran. Chem. Soc. 2011, 8:1-23.
56. Singh L.R., Chen X., Kozich V., Kruger W.D. Chemical chaperone rescue of mutant human cystathionine beta-synthase. Mol. Genet. Metab. 2007, 91:335-342.
57. Kopecka J., Krijt J., Rakova K., Kozich V. Restoring assembly and activity of cystathionine beta-synthase mutants by ligands and chemical chaperones. J. Inherit. Metab. Dis. 2011, 34:39-48.
58. Majtan T., Liu L., Carpenter J.F., Kraus J.P. Rescue of cystathionine beta-synthase (CBS) mutants with chemical chaperones: purification and characterization of eight CBS mutant enzymes. J. Biol. Chem. 2010, 285:15866-15873.
59. Melenovska P., Kopecka J., Krijt J., et al. Chaperone therapy for homocystinuria: the rescue of CBS mutations by heme arginate. J. Inherit. Metab. Dis. 2015, 38:287-294.
60. Majtan T., Singh L.R., Wang L., Kruger W.D., Kraus J.P. Active cystathionine beta-synthase can be expressed in heme-free systems in the presence of metal-substituted porphyrins or a chemical chaperone. J. Biol. Chem. 2008, 283:34588-34595.
61. Poddar N.K., Ansari Z.A., Singh R.K., Moosavi-Movahedi A.A., Ahmad F. Effect of monomeric and oligomeric sugar osmolytes on DeltaGD, the Gibbs energy of stabilization of the protein at different pH values: is the sum effect of monosaccharide individually additive in a mixture?. Biophys. Chem. 2008, 138:120-129.
62. Nau R. Osmotherapy for elevated intracranial pressure: a critical reappraisal. Clin. Pharmacokinet. 2000, 38:23-40.
63. Bross P., Corydon T.J., Andresen B.S., Jorgensen M.M., Bolund L., Gregersen N. Protein misfolding and degradation in genetic diseases. Hum. Mutat. 1999, 14:186-198.
64. Luo G.R., Chen S., Le W.D. Are heat shock proteins therapeutic target for Parkinson's disease?. Int. J. Biol. Sci. 2007, 3:20-26.
65. Muller P., Hrstka R., Coomber D., Lane D.P., Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008, 27:3371-3383.
66. Singh L.R., Gupta S., Honig N.H., Kraus J.P., Kruger W.D. Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70. PLoS Genet. 2010, 6:e1000807.
67. Gupta S., Wang L., Anderl J., Slifker M.J., Kirk C., Kruger W.D. Correction of cystathionine beta synthase deficiency in mice by treatment with proteasome inhibitors. Hum. Mutat. 2013, 34:1085-1093.
68. Lanka V., Wieland S., Barber J., Cudkowicz M. Arimoclomol: a potential therapy under development for ALS. Expert Opin. Investig. Drugs 2009, 18:1907-1918.
69. Salgia R., Berkenblit A., Dezube B., Dahl T.A., Koya K. STA-4783, a novel HSP inducer, enhances paclitaxel activity-preclinical to clinical modeling. J. Clin. Oncol. 2004, 22:3124.
70. Chwatko G., Jakubowski H. Urinary excretion of homocysteine-thiolactone in humans. Clin. Chem. 2005, 51:408-415.
71. Schwille P., Schmiedl A., Herrmann U., et al. Magnesium, citrate, magnesium citrate and magnesium-alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis. Urol. Res. 1999, 27:117-126.
72. Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J. Nutr. 2000, 130:377S-381S.
73. Billecke S., Draganov D., Counsell R., et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 2000, 28:1335-1342.
74. Bayrak A., Bayrak T., Demirpence E., Kilinc K. Differential hydrolysis of homocysteine thiolactone by purified human serum (192)Q and (192)R PON1 isoenzymes. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2011, 879:49-55.
75. Perla-Kajan J., Jakubowski H. Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J. 2010, 24:931-936.
76. Jakubowski H., Ambrosius W.T., Pratt J.H. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett. 2001, 491:35-39.
77. Zimny J., Sikora M., Guranowski A., Jakubowski H. Protective mechanisms against homocysteine toxicity: the role of bleomycin hydrolase. J. Biol. Chem. 2006, 281:22485-22492.
78. Bromme D., Rossi A.B., Smeekens S.P., Anderson D.C., Payan D.G. Human bleomycin hydrolase: molecular cloning, sequencing, functional expression, and enzymatic characterization. Biochemistry 1996, 35:6706-6714.
79. Puente X.S., Lopez-Otin C. Cloning and expression analysis of a novel human serine hydrolase with sequence similarity to prokaryotic enzymes involved in the degradation of aromatic compounds. J. Biol. Chem. 1995, 270:12926-12932.
80. Puente X.S., Pendas A.M., Lopez-otin C. Structural characterization and chromosomal localization of the gene encoding human biphenyl hydrolase-related protein (BPHL). Genomics 1998, 51:459-462.
81. Kim I., Chu X.Y., Kim S., Provoda C.J., Lee K.D., Amidon G.L. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J. Biol. Chem. 2003, 278:25348-25356.
82. Marsillach J., Suzuki S.M., Richter R.J., et al. Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase. PLoS One 2014, 9:e110054.
83. Schmidt D.E., Westheimer F.H. PK of the lysine amino group at the active site of acetoacetate decarboxylase. Biochemistry 1971, 10:1249-1253.
84. Gerig J.T., Reinheimer J.D. Modification of human serum albumin with trifluoromethyl-substituted aryl halides and sulfonates. J. Am. Chem. Soc. 1975, 97:168-173.
85. Garel J., Tawfik D.S. Mechanism of hydrolysis and aminolysis of homocysteine thiolactone. Chemistry 2006, 12:4144-4152.
86. Hollfelder F., Kirby A.J., Tawfik D.S. On the magnitude and specificity of medium effects in enzyme-like catalysts for proton transfer. J. Org. Chem. 2001, 66:5866-5874.
87. Andersson L.K., Caspersson M., Baltzer L. Control of lysine reactivity in four-helix bundle proteins by site-selective pKa depression: expanding the versatility of proteins by postsynthetic functionalization. Chemistry 2002, 8:3687-3697.
88. Endo N., Nishiyama K., Otsuka A., Kanouchi H., Taga M., Oka T. Antioxidant activity of vitamin B6 delays homocysteine-induced atherosclerosis in rats. Br. J. Nutr. 2006, 95:1088-1093.
89. Verhoef P., Kok F.J., Kruyssen D.A., et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 1997, 17:989-995.
90. Gates A.T., Lowry M., Fletcher K.A., et al. Capillary electrophoretic screening for the inhibition of homocysteine thiolactone-induced protein oligomerization. Anal. Chem. 2007, 79:8249-8256.
91. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell. Mol. Life Sci. 2004, 61:470-487.
92. Kumar T., Sharma G.S., Singh L.R. Existence of molten globule state in homocysteine-induced protein covalent modifications. PLoS One 2014, 9:e113566.
93. Sharma G.S., Kumar T., Dar T.A., Singh L.R. Protein N-homocysteinylation: from cellular toxicity to neurodegeneration. Biochim. Biophys. Acta 1850, 2015:2239-2245.
94. Sharma G.S., Kumar T., Singh L.R. N-homocysteinylation induces different structural and functional consequences on acidic and basic proteins. PLoS One 2015, 9:e116386.
95. Bolen D.W., Baskakov I.V. The osmophobic effect: natural selection of a thermodynamic force in protein folding. J. Mol. Biol. 2001, 310:955-963.
96. Bolen D.W. Effects of naturally occurring osmolytes on protein stability and solubility: issues important in protein crystallization. Methods 2004, 34:312-322.
97. Auton M., Bolen D.W. Predicting the energetics of osmolyte-induced protein folding/unfolding. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15065-15068.
98. Samuel D., Kumar T.K.S., Ganesh G., et al. Proline inhibits aggregation during protein refolding. Protein Sci. 2000, 9:344-352.
99. Kumat T.K.S., Samuel D., Jayaraman G., Srimathi T., Yu C. The role of proline in the prevention of aggregation during protein folding in vitro. IUBMB Life 1998, 46:509-517.
100. Ignatova Z., Gierasch L.M. Inhibition of protein aggregation in vitro and in vivo by a natural osmoprotectant. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13357-13361.
101. Outinen P.A., Sood S.K., Pfeifer S.I., et al. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 1999, 94:959-967.
102. Jr Matysik, Bhalu B., Mohanty P. Molecular mechanisms of quenching of reactive oxygen species by proline under stress in plants. Curr. Sci. 2002, 82:525-532.
103. Yu J., Kim A.K. Effect of taurine on antioxidant enzyme system in B16F10 melanoma cells. Adv. Exp. Med. Biol. 2009, 643:491-499.
104. Jiang H., Stabler S.P., Allen R.H., Abman S.H., Maclean K.N. Altered hepatic sulfur metabolism in cystathionine beta-synthase-deficient homocystinuria: regulatory role of taurine on competing cysteine oxidation pathways. FASEB J. 2014, 28:4044-4054.
105. Nonaka H., Tsujino T., Watari Y., Emoto N., Yokoyama M. Taurine prevents the decrease in expression and secretion of extracellular superoxide dismutase induced by homocysteine: amelioration of homocysteine-induced endoplasmic reticulum stress by taurine. Circulation 2001, 104:1165-1170.
106. Scholze A., Rinder C., Beige J., Riezler R., Zidek W., Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004, 109:369-374.
107. Wiklund O., Fager G., Andersson A., Lundstam U., Masson P., Hultberg B. N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels. Atherosclerosis 1996, 119:99-106.